Bracco had alleged that Jubilant’s RUBY-FILL^® Generator and RUBY Rubidium Elution System™ were infringing the two patents in a lawsuit filed in 2018, prompting Jubilant to challenge the validity of the two patents in three Inter Partes Review (“IPR”) proceedings before the U.S. Patent Office. As a result of these favorable rulings, the U.S. Patent Office is expected to cancel all challenged claims of the two Bracco patents.

This favorable decision from the U.S. Patent Office comes on the heels of another favorable ruling that Jubilant received in December 2019 from the U.S. International Trade Commission (“ITC”), which found three other Bracco patents directed to rubidium infusion systems invalid. The ITC proceeding was instituted in 2018 after Bracco filed a complaint with the ITC accusing Jubilant’s RUBY-FILL Generator and RUBY Rubidium Elution System of infringing the three patents. As a result of the ITC’s invalidity findings, the ITC found Jubilant had not violated section 337 of the Tariff Act of 1930 and terminated the proceeding in Jubilant’s favor.

“These favorable rulings by the U.S. Patent Office and International Trade Commission further confirm Jubilant’s right to continue development and commercialization of RUBY-FILL in the U.S. marketplace and to continue focusing on our goal of bringing innovative products to the market for patients in need of the latest technology,” stated Pramod Yadav, CEO, Jubilant Pharma Limited.

Jubilant Radiopharma’s RUBY-FILL Generator and RUBY Rubidium Elution System provide the latest and most advanced technology in PET Rubidium-82 myocardial imaging. RUBY-FILL provides customers a choice in the next generation product, with safety, efficiency, and automation advancements. Jubilant Radiopharma’s products are key in its greater commitment to investing in the growth and expansion of nuclear medicine in the global market.

For more information on RUBY-FILL and the RUBY Rubidium Elution System’s technology features and benefits, please visit the website at www.RUBY-FILL.com or www.jubilantradiopharma.com.

ABOUT JUBILANT RADIOPHARMA™: Jubilant Radiopharma, Radiopharmaceutical Division of Jubilant Pharma Ltd., is an industry-leading radiopharmaceutical business focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of “Improving Lives Through Nuclear Medicine” on a global scale.

ABOUT JUBILANT PHARMA LIMITED: Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and awholly-owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non- sterile products through 6 USFDA approved manufacturing facilities in the US, Canada and India and a network of over 50 radio-pharmacies in the US. The Company has a team of over 4,300 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceuti companies globally.

No. BILLERICA, Mass. (January 29, 2015) – Lantheus Medical Imaging, Inc. (Lantheus), a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of a Supplemental New Drug Application (sNDA) that allows Jubilant HollisterStier (JHS) to be a new manufacturing site for its proprietary brain perfusion imaging agent NEUROLITE® (Kit of the Preparation of Technetium Tc99m Bicisate for Injection). NEUROLITE, a technetium-based single-photon emission computed tomography (SPECT) radiopharmaceutical agent, provides healthcare providers with critical neurological information for patients.

“FDA approval of JHS as a new manufacturer for NEUROLITE is a major step forward in ensuring that there is long-term, sufficient supply of NEUROLITE available to meet market demand for brain perfusion imaging agents,” said Jeff Bailey, President and CEO of Lantheus. “We are pleased to partner with JHS for the manufacture of high quality products, including NEUROLITE and DEFINITY.”

Recently, Lantheus received approval from the Therapeutic Goods Administration (TGA) of Australia and the Pharmaceutical and Medical Devices Agency of Japan for JHS-manufactured NEUROLITE.

JHS also serves as an approved manufacturer of DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension for contrast-enhanced echocardiography.

About NEUROLITE®
NEUROLITE® (Kit of the Preparation of Technetium Tc99m Bicisate for Injection) is a SPECT brain imaging agent for use to identify the area within the brain where blood flow has been blocked or reduced due to stroke.

INDICATIONS
NEUROLITE single photon emission computerized tomography (SPECT) is indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed. NEUROLITE is not indicated for assessment of functional viability of brain tissue or for distinguishing between stroke and other brain lesions.

CONTRAINDICATIONS
None known.

Important Safety Information
In clinical trials, NEUROLITE has been administered to 1063 subjects (255 normals, 808 patients). In the 808 patients with neurologic events, there were 11 (1.4%) deaths, none of which were clearly attributed to NEUROLITE. The following adverse effects were observed in < 1% of the subjects: headache, dizziness, seizure, agitation/anxiety, malaise/somnolence, parosmia, hallucinations, rash, nausea, syncope, cardiac failure, hypertension, angina, and apnea/cyanosis.

No. BILLERICA, Mass. (January 29, 2015) – Lantheus Medical Imaging, Inc. (Lantheus), a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of a Supplemental New Drug Application (sNDA) that allows Jubilant HollisterStier (JHS) to be a new manufacturing site for its proprietary brain perfusion imaging agent NEUROLITE® (Kit of the Preparation of Technetium Tc99m Bicisate for Injection). NEUROLITE, a technetium-based single-photon emission computed tomography (SPECT) radiopharmaceutical agent, provides healthcare providers with critical neurological information for patients.

“FDA approval of JHS as a new manufacturer for NEUROLITE is a major step forward in ensuring that there is long-term, sufficient supply of NEUROLITE available to meet market demand for brain perfusion imaging agents,” said Jeff Bailey, President and CEO of Lantheus. “We are pleased to partner with JHS for the manufacture of high quality products, including NEUROLITE and DEFINITY.”

Recently, Lantheus received approval from the Therapeutic Goods Administration (TGA) of Australia and the Pharmaceutical and Medical Devices Agency of Japan for JHS-manufactured NEUROLITE.

JHS also serves as an approved manufacturer of DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension for contrast-enhanced echocardiography.

About NEUROLITE®
NEUROLITE® (Kit of the Preparation of Technetium Tc99m Bicisate for Injection) is a SPECT brain imaging agent for use to identify the area within the brain where blood flow has been blocked or reduced due to stroke.

INDICATIONS
NEUROLITE single photon emission computerized tomography (SPECT) is indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed. NEUROLITE is not indicated for assessment of functional viability of brain tissue or for distinguishing between stroke and other brain lesions.

CONTRAINDICATIONS
None known.

Important Safety Information
In clinical trials, NEUROLITE has been administered to 1063 subjects (255 normals, 808 patients). In the 808 patients with neurologic events, there were 11 (1.4%) deaths, none of which were clearly attributed to NEUROLITE. The following adverse effects were observed in < 1% of the subjects: headache, dizziness, seizure, agitation/anxiety, malaise/somnolence, parosmia, hallucinations, rash, nausea, syncope, cardiac failure, hypertension, angina, and apnea/cyanosis.

Spokane, Washington, USA, June 12, 2014 - Local pharmaceutical manufacturing company, Jubilant HollisterStier, is pleased to announce the appointment of Mr. Bill Simmons as President for the company’s Contract Manufacturing Organization (CMO).  Mr. Simmons is a seasoned senior executive with over 26 years in leadership roles.  His experience with the pharma industry is inclusive of contract manufacturing; proprietary, generic, and OTC pharmaceuticals; medical devices and capital equipment; home healthcare; and agricultural chemicals.  He has held various leadership positions with Baxter and Lederle Laboratories and was EVP and COO of Mayne Pharma LTD where he was responsible for $622mm in sales and 1,700 employees.  Mr. Simmons will oversee the continued growth of the CMO facilities located in Spokane, Washington, U.S.A. and Montreal, Quebec, CAN.  He holds an MBA and a BS in Chemistry.

About Jubilant HollisterStier

Jubilant HollisterStier provides pharmaceutical products and services to the global Life Sciences market.  Located in Spokane, Washington, U.S.A., the facility houses two business units, Jubilant HollisterStier Contract Manufacturing & Services Division and HollisterStier Allergy.  Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Jubilant HollisterStier is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  For more info about Jubilant HollisterStier Contract Manufacturing & Services Division, please, visit jublHS.com.  For more information about HollisterStier Allergy, please visit HSallergy.com  Our parent company can be found at jubl.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery and Development. The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of around 6200 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com

Spokane, Washington, USA, June 12, 2014 - Local pharmaceutical manufacturing company, Jubilant HollisterStier, is pleased to announce the appointment of Mr. Bill Simmons as President for the company’s Contract Manufacturing Organization (CMO).  Mr. Simmons is a seasoned senior executive with over 26 years in leadership roles.  His experience with the pharma industry is inclusive of contract manufacturing; proprietary, generic, and OTC pharmaceuticals; medical devices and capital equipment; home healthcare; and agricultural chemicals.  He has held various leadership positions with Baxter and Lederle Laboratories and was EVP and COO of Mayne Pharma LTD where he was responsible for $622mm in sales and 1,700 employees.  Mr. Simmons will oversee the continued growth of the CMO facilities located in Spokane, Washington, U.S.A. and Montreal, Quebec, CAN.  He holds an MBA and a BS in Chemistry.

About Jubilant HollisterStier

Jubilant HollisterStier provides pharmaceutical products and services to the global Life Sciences market.  Located in Spokane, Washington, U.S.A., the facility houses two business units, Jubilant HollisterStier Contract Manufacturing & Services Division and HollisterStier Allergy.  Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Jubilant HollisterStier is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  For more info about Jubilant HollisterStier Contract Manufacturing & Services Division, please, visit jublHS.com.  For more information about HollisterStier Allergy, please visit HSallergy.com  Our parent company can be found at jubl.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery and Development. The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of around 6200 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com

Montreal, QC, Canada., August 14, 2013  Jubilant HollisterStier announced today that the Montreal-based manufacturing facility has completed the first phase of an expansion of their sterile manufacturing capacity, with the addition of a new ampoule filling line utilizing a rigid barrier system. This expansion of capacity is a continuation of improvements being made to further enhance the site’s sterile manufacturing capabilities. 

The new manufacturing area will expand ampoule manufacturing capacity in Montreal  by nearly two hundred percent.  In addition, expansions to the sterile areas at Jubilant HollisterStier have been optimized through successful implementation of Lean and Six Sigma initiatives.

The new area is scheduled to be ready for product on September 9th 2013. A significant portion of the expanded capacity has already been allocated to new customer products that will be manufactured at the site.

“We are excited to complete this phase of our optimization strategy in sterile manufacturing.  Our site in Montreal will be well positioned to continue offering multiple dosage platforms for our global customers. We have been fortunate to secure several new contracts that will utilize our expanded capacity starting this year” said Jubilant HollisterStier Chief Executive Officer, Marcelo Morales.

About Jubilant HollisterStier

Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. Jubilant HollisterStier provides its customers manufacturing services to aseptically fill liquid and lyophilized products and semi-solid dosage forms at its facility in Montreal, Quebec, Canada. For more info about Jubilant HollisterStier, visit jublHS.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of almost 6400 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 90 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Montreal, QC, Canada., August 14, 2013  Jubilant HollisterStier announced today that the Montreal-based manufacturing facility has completed the first phase of an expansion of their sterile manufacturing capacity, with the addition of a new ampoule filling line utilizing a rigid barrier system. This expansion of capacity is a continuation of improvements being made to further enhance the site’s sterile manufacturing capabilities. 

The new manufacturing area will expand ampoule manufacturing capacity in Montreal  by nearly two hundred percent.  In addition, expansions to the sterile areas at Jubilant HollisterStier have been optimized through successful implementation of Lean and Six Sigma initiatives.

The new area is scheduled to be ready for product on September 9th 2013. A significant portion of the expanded capacity has already been allocated to new customer products that will be manufactured at the site.

“We are excited to complete this phase of our optimization strategy in sterile manufacturing.  Our site in Montreal will be well positioned to continue offering multiple dosage platforms for our global customers. We have been fortunate to secure several new contracts that will utilize our expanded capacity starting this year” said Jubilant HollisterStier Chief Executive Officer, Marcelo Morales.

About Jubilant HollisterStier

Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. Jubilant HollisterStier provides its customers manufacturing services to aseptically fill liquid and lyophilized products and semi-solid dosage forms at its facility in Montreal, Quebec, Canada. For more info about Jubilant HollisterStier, visit jublHS.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of almost 6400 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 90 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Media Contact:   Shannon Jordan, 509.482.4958

Spokane, Washington, USA, June 5, 2013 Local pharmaceutical manufacturing company, Jubilant HollisterStier, is pleased to announce the addition of Kirt Walker as the new Director of Human Resources.  Kirt holds a degree in Human Resources from Utah State University and has 17 years of experience, most recently as HR Director for a large pharmaceutical company in Pennsylvania and Virginia.   Kirt will be supporting corporate strategies and community outreach activities for the Spokane facility.  Jubilant HollisterStier employs 650 personnel including scientists, engineers, quality control,  manufacturing, business development, and support staff.

About Jubilant HollisterStier 

Jubilant HollisterStier provides pharmaceutical products and services to the global Life Sciences market.  Located in Spokane, Washington, U.S.A., the facility houses two business units, Jubilant HollisterStier Contract Manufacturing & Services Division and HollisterStier Allergy.  Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. The Spokane site has been in operation since 1921 and offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Jubilant HollisterStier is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  For more information about Jubilant HollisterStier Contract Manufacturing & Services Division, please, visit jublHS.com.  For more information about HollisterStier Allergy, please visit HSallergy.com  Our parent company can be found at jubl.com.

About Jubilant Life Sciences 

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of almost 6400 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 90 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Media Contact:   Shannon Jordan, 509.482.4958

Spokane, Washington, USA, June 5, 2013 Local pharmaceutical manufacturing company, Jubilant HollisterStier, is pleased to announce the addition of Kirt Walker as the new Director of Human Resources.  Kirt holds a degree in Human Resources from Utah State University and has 17 years of experience, most recently as HR Director for a large pharmaceutical company in Pennsylvania and Virginia.   Kirt will be supporting corporate strategies and community outreach activities for the Spokane facility.  Jubilant HollisterStier employs 650 personnel including scientists, engineers, quality control,  manufacturing, business development, and support staff.

About Jubilant HollisterStier 

Jubilant HollisterStier provides pharmaceutical products and services to the global Life Sciences market.  Located in Spokane, Washington, U.S.A., the facility houses two business units, Jubilant HollisterStier Contract Manufacturing & Services Division and HollisterStier Allergy.  Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. The Spokane site has been in operation since 1921 and offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Jubilant HollisterStier is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  For more information about Jubilant HollisterStier Contract Manufacturing & Services Division, please, visit jublHS.com.  For more information about HollisterStier Allergy, please visit HSallergy.com  Our parent company can be found at jubl.com.

About Jubilant Life Sciences 

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of almost 6400 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 90 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

DCAT, March 11-14 
Waldorf-Astoria Hotel, NYC 
In attendance:
Marcelo Morales, CEO; Curtis Gingles, VP Marketing & Sales; Carolyn Gudz, NA Director, Business Development 

World Vaccine Congress, April 16-18 
Gaylord National Hotel and Convention Cntr, Washington D.C 
In attendance:
Curtis Gingles, Vice President of Marketing & Sales; David Linn, Director of Business Intelligence and Development

Interphex NYC, April 23-25, booth 3923
Jacob Javitz Center 
In attendance:

• Marcelo Morales, CEO
• Jeff Milligan, VP Operations and Business Excellence
• Curtis Gingles, VP of Marketing & Sales
• Peggy Sowers, Senior Manager, Business Dev.
• Brad Arnold, Manager, Business Dev.
• Sandra Maki, Account Manager
• Mara Candido, Director of Commercial Operations

Bio International Convention, April 22-25, booth 2170 
McCormick Place, Chicago, IL
In attendance:
Marcelo Morales, CEO; Carolyn Gudz, North American Director, Business Development; David Linn, Director of Business Intelligence and Development

CPhI Japan, April 24-26, (in Jubilant Life Sciences'stand, F-16)
Big Sight Exhibition Center, Tokyo
In attendance:
David Flowers, Director of Business Development

DCAT, March 11-14 
Waldorf-Astoria Hotel, NYC 
In attendance:
Marcelo Morales, CEO; Curtis Gingles, VP Marketing & Sales; Carolyn Gudz, NA Director, Business Development 

World Vaccine Congress, April 16-18 
Gaylord National Hotel and Convention Cntr, Washington D.C 
In attendance:
Curtis Gingles, Vice President of Marketing & Sales; David Linn, Director of Business Intelligence and Development

Interphex NYC, April 23-25, booth 3923
Jacob Javitz Center 
In attendance:

• Marcelo Morales, CEO
• Jeff Milligan, VP Operations and Business Excellence
• Curtis Gingles, VP of Marketing & Sales
• Peggy Sowers, Senior Manager, Business Dev.
• Brad Arnold, Manager, Business Dev.
• Sandra Maki, Account Manager
• Mara Candido, Director of Commercial Operations

Bio International Convention, April 22-25, booth 2170 
McCormick Place, Chicago, IL
In attendance:
Marcelo Morales, CEO; Carolyn Gudz, North American Director, Business Development; David Linn, Director of Business Intelligence and Development

CPhI Japan, April 24-26, (in Jubilant Life Sciences'stand, F-16)
Big Sight Exhibition Center, Tokyo
In attendance:
David Flowers, Director of Business Development

Spokane, WA, U.S.A., November 13, 2012  Jubilant HollisterStier, a subsidiary of Jubilant Life Sciences, announced today that its Contract Manufacturing & Services division has recently secured over $100M USD contracts with leading pharmaceutical companies for the commercial manufacturing of multiple sterile parenteral products. These awards are the continuation of existing relationships and will be executed across both parenteral manufacturing locations in Spokane WA, and Montreal Canada. The commercial technology transfer efforts are expected to commence in 2013.

"We are excited to expand our existing strategic commercial relationships, and will bring forward our capabilities in manufacturing excellence, rigorous quality oversight and project management to support a smooth and timely transfer to our manufacturing locations, said Jubilant HollisterStier Chief Executive Officer, Marcelo Morales.

About Jubilant HollisterStier Contract Manufacturing & Services Division

Jubilant HollisterStier Contract Manufacturing & Services Division is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. Jubilant HollisterStier provides its customers manufacturing services to aseptically fill liquid and lyophilized products, semi-solid and solid dosage forms at its facilities in the United States, Canada, and India. Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Jubilant HollisterStier is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  For more info about Jubilant HollisterStier, visit jublHS.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of almost 6400 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 90 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com

Media Contact:
Shannon Jordan, 509.482.4958

Spokane, WA, U.S.A., November 13, 2012  Jubilant HollisterStier, a subsidiary of Jubilant Life Sciences, announced today that its Contract Manufacturing & Services division has recently secured over $100M USD contracts with leading pharmaceutical companies for the commercial manufacturing of multiple sterile parenteral products. These awards are the continuation of existing relationships and will be executed across both parenteral manufacturing locations in Spokane WA, and Montreal Canada. The commercial technology transfer efforts are expected to commence in 2013.

"We are excited to expand our existing strategic commercial relationships, and will bring forward our capabilities in manufacturing excellence, rigorous quality oversight and project management to support a smooth and timely transfer to our manufacturing locations, said Jubilant HollisterStier Chief Executive Officer, Marcelo Morales.

About Jubilant HollisterStier Contract Manufacturing & Services Division

Jubilant HollisterStier Contract Manufacturing & Services Division is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. Jubilant HollisterStier provides its customers manufacturing services to aseptically fill liquid and lyophilized products, semi-solid and solid dosage forms at its facilities in the United States, Canada, and India. Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Jubilant HollisterStier is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  For more info about Jubilant HollisterStier, visit jublHS.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of almost 6400 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 90 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com

Media Contact:
Shannon Jordan, 509.482.4958

Jubilant HollisterStier Announces Launch of Analytical Services Division

Spokane, WA, U.S.A., September 21, 2012  Jubilant HollisterStier announced today that its Contract Manufacturing & Services division has launched an analytical services unit that will provide laboratory method development and related analytical testing as part of its integrated service offerings. Jubilant HollisterStier will offer a full suite of testing capabilities,  including Raw Materials Testing, Release Testing, Microbiology testing, Laboratory Method Development & Validation, Impurities Testing and Stability Testing & Storage. These capabilities will be available through its facilities in Spokane, Washington, USA and Montreal, Quebec, Canada.

“The launch of our analytical services offerings is a continuation of our strategy to be a leading provider of services to the Life Sciences industry.  We are expanding our analytical capabilities to support a wide array of high-quality laboratory tests, aimed at further servicing our clients and partners.” said Marcelo Morales, Chief Executive Officer, Jubilant HollisterStier

About Jubilant HollisterStier Contract Manufacturing & Services Division

Jubilant HollisterStier Contract Manufacturing & Services Division is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. Jubilant HollisterStier provides its customers manufacturing services to aseptically fill liquid and lyophilized products, semi-solid and solid dosage forms at its facilities in the United States, Canada, and India. Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Jubilant HollisterStier is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  For more info about Jubilant HollisterStier, visit jublHS.com.

Media Contact:
Shannon Jordan, 509.482.4958

Jubilant HollisterStier Announces Launch of Analytical Services Division

Spokane, WA, U.S.A., September 21, 2012  Jubilant HollisterStier announced today that its Contract Manufacturing & Services division has launched an analytical services unit that will provide laboratory method development and related analytical testing as part of its integrated service offerings. Jubilant HollisterStier will offer a full suite of testing capabilities,  including Raw Materials Testing, Release Testing, Microbiology testing, Laboratory Method Development & Validation, Impurities Testing and Stability Testing & Storage. These capabilities will be available through its facilities in Spokane, Washington, USA and Montreal, Quebec, Canada.

“The launch of our analytical services offerings is a continuation of our strategy to be a leading provider of services to the Life Sciences industry.  We are expanding our analytical capabilities to support a wide array of high-quality laboratory tests, aimed at further servicing our clients and partners.” said Marcelo Morales, Chief Executive Officer, Jubilant HollisterStier

About Jubilant HollisterStier Contract Manufacturing & Services Division

Jubilant HollisterStier Contract Manufacturing & Services Division is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. Jubilant HollisterStier provides its customers manufacturing services to aseptically fill liquid and lyophilized products, semi-solid and solid dosage forms at its facilities in the United States, Canada, and India. Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Jubilant HollisterStier is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  For more info about Jubilant HollisterStier, visit jublHS.com.

Media Contact:
Shannon Jordan, 509.482.4958

Spokane, WA, U.S.A., February 21, 2012  Jubilant HollisterStier (formerly Hollister-Stier Laboratories LLC), a subsidiary of Jubilant Life Sciences, announced today that its Contract Manufacturing & Services division has recently secured contracts with four innovator life science companies for the commercial manufacturing of sterile parenteral products for sale in the United States and Europe. These agreements will be executed at its Spokane, Washington facility for contract manufacturing of products ranging from liquid to lyophilization presentations, across a variety of patient indications. The total value of these contracts is over US $ 90 million to be delivered over a 5 year period. Commercial transfer to the Jubilant HollisterStier manufacturing facility has commenced for all contracts.

“We have successfully helped provide safe and effective products to innovator Pharmaceutical and Biotechnology companies over the years and are committed to do so for these products as well. We are pleased to offer our support in the development and manufacture of highly complex products through the application of leading scientific solutions and utmost dedication to quality and customer service. This expansion of our globally leading parenteral manufacturing capabilities is a further outcome of our strategy to extend our offering across products and geographies.” said Marcelo Morales, Chief Executive Officer, Jubilant HollisterStier

Commenting on the multi-million dollar award, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said, “We are pleased with signing of these long term contracts with innovator pharma companies to serve the regulated markets of US and Europe and is a direct result of our increased business development efforts leading to higher utilization of our existing capacity. Jubilant is one of the leading manufacturers of sterile both liquid and lyophilized products in North America.”

About Jubilant HollisterStier

Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. Jubilant HollisterStier provides its customers manufacturing services to aseptically fill liquid and lyophilized products, semi-solid and solid dosage forms at its facilities in the United States, Canada, and India. Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Jubilant HollisterStier is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  For more info about Jubilant HollisterStier, visit jublHS.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited is an integrated Pharma and Life Sciences Company. It is the largest Custom Research and Manufacturing Services (CRAMS) player and a leading Drug Discovery and Development Solution provider out of India. The Company provides Life Sciences products and services across the value chain.  With 10 world-class manufacturing facilities and a team of 6,200 multicultural people across the globe, the Company is committed to deliver value to its customers spread across 75 countries.  The Company is well recognized as a ‘Partner of Choice’ by leading life sciences companies worldwide.  For more info: www.jubl.com

For more information please contact:

For Media
Shannon Jordan, 509.482.4958

For Investors

Spokane, WA, U.S.A., February 21, 2012  Jubilant HollisterStier (formerly Hollister-Stier Laboratories LLC), a subsidiary of Jubilant Life Sciences, announced today that its Contract Manufacturing & Services division has recently secured contracts with four innovator life science companies for the commercial manufacturing of sterile parenteral products for sale in the United States and Europe. These agreements will be executed at its Spokane, Washington facility for contract manufacturing of products ranging from liquid to lyophilization presentations, across a variety of patient indications. The total value of these contracts is over US $ 90 million to be delivered over a 5 year period. Commercial transfer to the Jubilant HollisterStier manufacturing facility has commenced for all contracts.

“We have successfully helped provide safe and effective products to innovator Pharmaceutical and Biotechnology companies over the years and are committed to do so for these products as well. We are pleased to offer our support in the development and manufacture of highly complex products through the application of leading scientific solutions and utmost dedication to quality and customer service. This expansion of our globally leading parenteral manufacturing capabilities is a further outcome of our strategy to extend our offering across products and geographies.” said Marcelo Morales, Chief Executive Officer, Jubilant HollisterStier

Commenting on the multi-million dollar award, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said, “We are pleased with signing of these long term contracts with innovator pharma companies to serve the regulated markets of US and Europe and is a direct result of our increased business development efforts leading to higher utilization of our existing capacity. Jubilant is one of the leading manufacturers of sterile both liquid and lyophilized products in North America.”

About Jubilant HollisterStier

Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. Jubilant HollisterStier provides its customers manufacturing services to aseptically fill liquid and lyophilized products, semi-solid and solid dosage forms at its facilities in the United States, Canada, and India. Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Jubilant HollisterStier is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  For more info about Jubilant HollisterStier, visit jublHS.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited is an integrated Pharma and Life Sciences Company. It is the largest Custom Research and Manufacturing Services (CRAMS) player and a leading Drug Discovery and Development Solution provider out of India. The Company provides Life Sciences products and services across the value chain.  With 10 world-class manufacturing facilities and a team of 6,200 multicultural people across the globe, the Company is committed to deliver value to its customers spread across 75 countries.  The Company is well recognized as a ‘Partner of Choice’ by leading life sciences companies worldwide.  For more info: www.jubl.com

For more information please contact:

For Media
Shannon Jordan, 509.482.4958

For Investors

Montreal, Quebec, Canada, September 14, 2011- Jubilant HollisterStier Contract Manufacturing announced today that their Montreal-based facility has entered into a four year contract to manufacture a leading over the counter (OTC) prescription-strength treatment product with the total revenue being over $70M during that time period.

“We have successfully helped provide safe and effective products to consumers over the course of many years and look forward to continuing to do so for this product.  The addition to our globally leading OCL (ointment, creams, liquids) capabilities is a further strength of our strategy to expand our offering across products and geographies.” said Marcelo Morales, Chief Executive Officer, Jubilant HollisterStier, Contract Manufacturing & Services.”

About Jubilant HollisterStier

Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. Through its Contract Manufacturing & Services division it provides its customers global manufacturing services to aseptically fill liquid and lyophilized products as well as semi-solid and solid dosage forms at its facilities in the United States, Canada, and India. Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Jubilant HollisterStier is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  For more info about Jubilant HollisterStier, visit jublHS.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited, is an integrated Pharma and Life Sciences Company.  It is the largest Custom Research and Manufacturing Services (CRAMS) Company and a leading Drug Discovery & Development Solutions provider out of India. The Company provides Life Sciences products and services across the value chain.  With 10 world-class manufacturing facilities and a team of ~5800 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 75 countries. The Company is well recognized as a “Partner of Choice” by leading life sciences companies worldwide. Its revenues for FY 2011 stood at  US$ 770 Mn.  For more info: www.jubl.com

Media Inquiries
Shannon Jordan, 509.482.4958

Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences and its subsidiaries may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company’s filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Montreal, Quebec, Canada, September 14, 2011- Jubilant HollisterStier Contract Manufacturing announced today that their Montreal-based facility has entered into a four year contract to manufacture a leading over the counter (OTC) prescription-strength treatment product with the total revenue being over $70M during that time period.

“We have successfully helped provide safe and effective products to consumers over the course of many years and look forward to continuing to do so for this product.  The addition to our globally leading OCL (ointment, creams, liquids) capabilities is a further strength of our strategy to expand our offering across products and geographies.” said Marcelo Morales, Chief Executive Officer, Jubilant HollisterStier, Contract Manufacturing & Services.”

About Jubilant HollisterStier

Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. Through its Contract Manufacturing & Services division it provides its customers global manufacturing services to aseptically fill liquid and lyophilized products as well as semi-solid and solid dosage forms at its facilities in the United States, Canada, and India. Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Jubilant HollisterStier is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  For more info about Jubilant HollisterStier, visit jublHS.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited, is an integrated Pharma and Life Sciences Company.  It is the largest Custom Research and Manufacturing Services (CRAMS) Company and a leading Drug Discovery & Development Solutions provider out of India. The Company provides Life Sciences products and services across the value chain.  With 10 world-class manufacturing facilities and a team of ~5800 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 75 countries. The Company is well recognized as a “Partner of Choice” by leading life sciences companies worldwide. Its revenues for FY 2011 stood at  US$ 770 Mn.  For more info: www.jubl.com

Media Inquiries
Shannon Jordan, 509.482.4958

Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences and its subsidiaries may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company’s filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

HollisterStier Contract Manufacturing, Spokane, Washington, USA, and Draxis Pharma General Partnership, Kirkland , Quebec, Canada, announced today that they have formally aligned the branding of their contract manufacturing & services under the name Jubilant HollisterStier .  This change comes as a part of the  corporate-wide branding alignment by their India-based parent company, Jubilant Life Sciences.  

Jubilant HollisterStier Contract Manufacturing & Services, through individual operating companies in the United States and in Canada, offers high quality contract manufacturing and related services for the global pharmaceutical and biopharmaceutical market, across the full spectrum of clinical and commercial pharmaceutical requirements.  The new name and logo for Jubilant HollisterStier will represent the parenteral, semi-solid and solid dosage manufacturing, development and related services across North America.  

“The change to our branded name and image allows our organizations to more cohesively align with our parent company, Jubilant Life Sciences” said Marcelo Morales, Chief Executive Officer, Jubilant HollisterStier, Contract Manufacturing & Services.  “Since having been acquired by Jubilant three years ago, we have expanded our service offerings to include multiple dosage forms and services throughout the entire life sciences value chain.  This new name and logo completes our transition and full integration into Jubilant Life Sciences a leading Integrated Pharma & Life Sciences company, and more clearly communicates our breadth of service offerings available through this association”.

About Jubilant HollisterStier Contract Manufacturing & Services

Jubilant HollisterStier Contract Manufacturing & Services (JHSCMS) is a global manufacturing service provider, able to aseptically fill liquid and lyophilized products, semi-solid and solid dosage forms at its facilities in the United States, Canada, and India.  Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. JHSCMS is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and Life Sciences player, headquartered in India. For more information about Jubilant HollisterStier, visit HScontract.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited (formerly Jubilant Organosys Ltd) is an integrated Pharma and Life Sciences Company.  It is the largest Custom Research and Manufacturing Services (CRAMS) Company and a leading Drug Discovery & Development Solutions provider out of India. The Company provides Life Sciences products and services across the value chain.  With 10 world-class manufacturing facilities and a team of ~5700 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 65 countries. The Company is well recognized as a “Partner of Choice” by leading life sciences companies worldwide. Its revenues for FY 2010 stood at US$ 723 Mn. For more info: www.jubl.com

Media Inquiries:
Shannon Jordan, 509.482.4958

Disclaimer:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences and its subsidiaries may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company’s filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

HollisterStier Contract Manufacturing, Spokane, Washington, USA, and Draxis Pharma General Partnership, Kirkland , Quebec, Canada, announced today that they have formally aligned the branding of their contract manufacturing & services under the name Jubilant HollisterStier .  This change comes as a part of the  corporate-wide branding alignment by their India-based parent company, Jubilant Life Sciences.  

Jubilant HollisterStier Contract Manufacturing & Services, through individual operating companies in the United States and in Canada, offers high quality contract manufacturing and related services for the global pharmaceutical and biopharmaceutical market, across the full spectrum of clinical and commercial pharmaceutical requirements.  The new name and logo for Jubilant HollisterStier will represent the parenteral, semi-solid and solid dosage manufacturing, development and related services across North America.  

“The change to our branded name and image allows our organizations to more cohesively align with our parent company, Jubilant Life Sciences” said Marcelo Morales, Chief Executive Officer, Jubilant HollisterStier, Contract Manufacturing & Services.  “Since having been acquired by Jubilant three years ago, we have expanded our service offerings to include multiple dosage forms and services throughout the entire life sciences value chain.  This new name and logo completes our transition and full integration into Jubilant Life Sciences a leading Integrated Pharma & Life Sciences company, and more clearly communicates our breadth of service offerings available through this association”.

About Jubilant HollisterStier Contract Manufacturing & Services

Jubilant HollisterStier Contract Manufacturing & Services (JHSCMS) is a global manufacturing service provider, able to aseptically fill liquid and lyophilized products, semi-solid and solid dosage forms at its facilities in the United States, Canada, and India.  Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. JHSCMS is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and Life Sciences player, headquartered in India. For more information about Jubilant HollisterStier, visit HScontract.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited (formerly Jubilant Organosys Ltd) is an integrated Pharma and Life Sciences Company.  It is the largest Custom Research and Manufacturing Services (CRAMS) Company and a leading Drug Discovery & Development Solutions provider out of India. The Company provides Life Sciences products and services across the value chain.  With 10 world-class manufacturing facilities and a team of ~5700 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 65 countries. The Company is well recognized as a “Partner of Choice” by leading life sciences companies worldwide. Its revenues for FY 2010 stood at US$ 723 Mn. For more info: www.jubl.com

Media Inquiries:
Shannon Jordan, 509.482.4958

Disclaimer:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences and its subsidiaries may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company’s filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Jubilant HollisterStier is pleased to announce that Curtis Gingles has been hired as Vice President, Marketing & Sales for their Contract Manufacturing & Services Division.

Curtis has over 10 years of managerial experience in the pharmaceutical industry in various roles, including Quality, Manufacturing, and R&D.  For the past five years Curtis has served in Sales and Marketing positions at DSM Pharmaceuticals, Inc., starting as New Business Development Manager, then leading the Business Development group, and most recently leading the Business Development and Account Management groups. Prior to DSM, he was recognized at Abbott Laboratories and Hospira, Inc. for significant contributions in process and program management. Curtis holds a Bachelor of Science degree in Business Administration from Gardner Webb University.  Curtis will provide leadership to the Contract Manufacturing Business Development team for Jubilant HollisterStier

“Curtis has a proven track record as an individual contributor, a manager and a leader in securing new business and building lasting relationships with customers. He has established an extensive network of professionals in the pharmaceutical/ biopharmaceutical industry and is a strategic thinker in developing solutions to navigate the challenges of today’s extraordinary market conditions”, said Jubilant HollisterStier Chief Executive, Marcelo Morales.

About Jubilant HollisterStier Contract Manufacturing & Services

Jubilant HollisterStier Contract Manufacturing & Services (JHSCMS) (formerly HollisterStier Contract Manufacturing & Draxis Pharma) is a global manufacturing service provider, able to aseptically fill liquid and lyophilized products, semi-solid and solid dosage forms at its facilities in the United States, Canada, and India.  Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. JHSCMS is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and Life Sciences player, headquartered in India. For more information about Jubilant HollisterStier, visit jublHS.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited (formerly Jubilant Organosys Ltd) is an integrated Pharma and Life Sciences Company.  It is the largest Custom Research and Manufacturing Services (CRAMS) Company and a leading Drug Discovery & Development Solutions provider out of India. The Company provides Life Sciences products and services across the value chain.  With 10 world-class manufacturing facilities and a team of ~5700 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 65 countries. The Company is well recognized as a “Partner of Choice” by leading life sciences companies worldwide. Its revenues for FY 2010 stood at US$ 723 Mn. For more info: www.jubl.com

Media Inquiries:
Shannon Jordan, 509.482.4958

Disclaimer:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences and its subsidiaries may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company’s filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Jubilant HollisterStier is pleased to announce that Curtis Gingles has been hired as Vice President, Marketing & Sales for their Contract Manufacturing & Services Division.

Curtis has over 10 years of managerial experience in the pharmaceutical industry in various roles, including Quality, Manufacturing, and R&D.  For the past five years Curtis has served in Sales and Marketing positions at DSM Pharmaceuticals, Inc., starting as New Business Development Manager, then leading the Business Development group, and most recently leading the Business Development and Account Management groups. Prior to DSM, he was recognized at Abbott Laboratories and Hospira, Inc. for significant contributions in process and program management. Curtis holds a Bachelor of Science degree in Business Administration from Gardner Webb University.  Curtis will provide leadership to the Contract Manufacturing Business Development team for Jubilant HollisterStier

“Curtis has a proven track record as an individual contributor, a manager and a leader in securing new business and building lasting relationships with customers. He has established an extensive network of professionals in the pharmaceutical/ biopharmaceutical industry and is a strategic thinker in developing solutions to navigate the challenges of today’s extraordinary market conditions”, said Jubilant HollisterStier Chief Executive, Marcelo Morales.

About Jubilant HollisterStier Contract Manufacturing & Services

Jubilant HollisterStier Contract Manufacturing & Services (JHSCMS) (formerly HollisterStier Contract Manufacturing & Draxis Pharma) is a global manufacturing service provider, able to aseptically fill liquid and lyophilized products, semi-solid and solid dosage forms at its facilities in the United States, Canada, and India.  Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. JHSCMS is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and Life Sciences player, headquartered in India. For more information about Jubilant HollisterStier, visit jublHS.com.

About Jubilant Life Sciences

Jubilant Life Sciences Limited (formerly Jubilant Organosys Ltd) is an integrated Pharma and Life Sciences Company.  It is the largest Custom Research and Manufacturing Services (CRAMS) Company and a leading Drug Discovery & Development Solutions provider out of India. The Company provides Life Sciences products and services across the value chain.  With 10 world-class manufacturing facilities and a team of ~5700 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 65 countries. The Company is well recognized as a “Partner of Choice” by leading life sciences companies worldwide. Its revenues for FY 2010 stood at US$ 723 Mn. For more info: www.jubl.com

Media Inquiries:
Shannon Jordan, 509.482.4958

Disclaimer:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences and its subsidiaries may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company’s filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Spokane, Washington, U.S.A. September 22, 2010- HollisterStier Contract Manufacturing, U.S.A, a subsidiary of Jubilant Organosys Ltd., headquartered in India, announced today that it has earned the prestigious Manufacturer of the Year award presented by the Association of Washington Business (AWB) as part of their annual Manufacturing Excellence Awards. Selection criteria for this honor include a manufacturer's economic impact, productivity/quality improvements, corporate responsibility and workforce excellence. Washington State houses over 7,500 manufacturers and through this award, HollisterStier joins several multi-billion dollar Washington-based manufacturers who have previously been honored.

"HollisterStier has a deliberate set of systems and processes aimed at client satisfaction, employee engagement and empowerment and activity optimization. In meeting these three goals, our organization lends itself to continued quality innovation and improvement, corporate responsibility and workforce excellence. Our selection for this award is a testament to not only our successes in the highly complex industry of pharmaceutical manufacturing, but to the great employees we have here at HollisterStier -- this honor would not be possible without their hard work and dedication" said Marcelo Morales, Chief Executive Officer, HollisterStier Laboratories.

About HollisterStier Contract Manufacturing

HollisterStier Contract Manufacturing is a global manufacturing service provider, able to aseptically fill liquid and lyophilized products at our Spokane, Washington facility and semi-solid and solid dosage forms at our sister organizations located in Canada, the United States and India. HollisterStier Contract Manufacturing offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Along with our manufacturing partners, we are committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities. For more information about HollisterStier Contract Manufacturing as well as our parent and sister companies, please visit www.HScontract.com.

About Jubilant

JubilantOrganosys Ltd., an integrated pharmaceutical industry player, is the largest custom research and manufacturing services (CRAMS) Company out of India. The company has a presence across the pharmaceutical value chain for providing products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables& non-steriles products, radiopharmaceuticals, generic dosage forms, drug discovery services, medicinal chemistry services, clinical research services, Life Science Chemicals, Nutrition Ingredients and Health Care. The Company also manufactures Agri and Performance Polymer products.

Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys and its subsidiaries may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company's filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Spokane, Washington, U.S.A. September 22, 2010- HollisterStier Contract Manufacturing, U.S.A, a subsidiary of Jubilant Organosys Ltd., headquartered in India, announced today that it has earned the prestigious Manufacturer of the Year award presented by the Association of Washington Business (AWB) as part of their annual Manufacturing Excellence Awards. Selection criteria for this honor include a manufacturer's economic impact, productivity/quality improvements, corporate responsibility and workforce excellence. Washington State houses over 7,500 manufacturers and through this award, HollisterStier joins several multi-billion dollar Washington-based manufacturers who have previously been honored.

"HollisterStier has a deliberate set of systems and processes aimed at client satisfaction, employee engagement and empowerment and activity optimization. In meeting these three goals, our organization lends itself to continued quality innovation and improvement, corporate responsibility and workforce excellence. Our selection for this award is a testament to not only our successes in the highly complex industry of pharmaceutical manufacturing, but to the great employees we have here at HollisterStier -- this honor would not be possible without their hard work and dedication" said Marcelo Morales, Chief Executive Officer, HollisterStier Laboratories.

About HollisterStier Contract Manufacturing

HollisterStier Contract Manufacturing is a global manufacturing service provider, able to aseptically fill liquid and lyophilized products at our Spokane, Washington facility and semi-solid and solid dosage forms at our sister organizations located in Canada, the United States and India. HollisterStier Contract Manufacturing offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Along with our manufacturing partners, we are committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities. For more information about HollisterStier Contract Manufacturing as well as our parent and sister companies, please visit www.HScontract.com.

About Jubilant

JubilantOrganosys Ltd., an integrated pharmaceutical industry player, is the largest custom research and manufacturing services (CRAMS) Company out of India. The company has a presence across the pharmaceutical value chain for providing products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables& non-steriles products, radiopharmaceuticals, generic dosage forms, drug discovery services, medicinal chemistry services, clinical research services, Life Science Chemicals, Nutrition Ingredients and Health Care. The Company also manufactures Agri and Performance Polymer products.

Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys and its subsidiaries may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company's filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Spokane, Washington, U.S.A. March 15, 2010 - Jubilant Organosys, a leading integrated pharma and life sciences company headquartered in India, announced today that two of its contract manufacturing facilities in North America successfully completed regulatory authority cGMP audits, recently. HollisterStier Contract Manufacturing, based in Spokane Washington, U.S.A, completed a successful audit by the Japanese Pharmaceutical and Medical Device Agency (PMDA) for the review of a sterile injectable client product. Draxis Pharma, based in Montreal, Quebec, Canada, also completed a successful audit by the US Food and Drug Administration (FDA) and Health Canada.

HollisterStier

The audit by the Japanese Pharmaceutical and Medical Device Agency (PMDA) revealed no significant observations, which has resulted in a recommendation to the MHLW that Hollister-Stier be listed as an approved manufacturing site for the client's product. Independent of the PMDA audit, the HollisterStier facility was also recently approved by the European Medicines Agency (EMA) as a manufacturing site for this same product.

Draxis Pharma

The audit of Draxis Pharma by the US Food and Drug Administration (FDA) included a comprehensive cGMP review of both sterile parenteral and non-sterile semi-solid manufacturing capabilities and a Pre-Approval Inspection for three client products. No observations were received from this audit. Recommendations for site approvals for the three new client products are expected. The audit of Draxis Pharma by Health Canada focused on a cGMP review of a dedicated packaging capability and revealed no significant audit observations.

Marcelo Morales, CEO of HollisterStier Contract Manufacturing and Draxis Pharma, said "We are extremely pleased with the audit findings at both our HollisterStier and Draxis Pharma facilities. Maintaining a rigorous quality culture and robust quality systems, combined with effectively managing our clients' projects, assures the success of these projects in the global market place."

About Jubilant Organosys

Jubilant Organosys Ltd., an integrated pharmaceutical industry player, is the largest custom research and manufacturing services (CRAMS) out of India. The company has a presence across the pharmaceutical value chain for providing products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables & non-sterile products, radiopharmaceuticals, generic dosage forms, drug discovery services, medicinal chemistry services, clinical research services, Life Science Chemicals, Nutrition Ingredients and Health Care. The Company also manufactures Agri and Performance Polymer products. For more information please visit : www.jubl.com

About HollisterStier Contract Manufacturing and DRAXIS Pharma

HollisterStier Contract Manufacturing and DRAXIS Pharma are separately branded contract manufacturing organizations that joined capabilities and services under the ownership of Jubilant Organosys. HollisterStier is a global manufacturing service provider, able to aseptically fill liquid and lyophilized products at their Spokane, Washington, U.S.A., facility and DRAXIS Pharma offers manufacturing services for sterile liquid and sterile and non-sterile semi-solid dosage forms at their Montreal, Quebec, Canada, facility. Manufacturing facilities for solid dosage forms are also available in the United States and India through HollisterStier and DRAXIS.

 Both organizations offer highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. HollisterStier and DRAXIS are committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities. For more information about HollisterStier Contract Manufacturing, please visit HScontract.com and for more information about DRAXIS Pharma, visit www.DRAXISPharma.com.

HollisterStier-Draxis Pharma
Media Inquiries:
Shannon Jordan
509.482.4958

Spokane, Washington, U.S.A. March 15, 2010 - Jubilant Organosys, a leading integrated pharma and life sciences company headquartered in India, announced today that two of its contract manufacturing facilities in North America successfully completed regulatory authority cGMP audits, recently. HollisterStier Contract Manufacturing, based in Spokane Washington, U.S.A, completed a successful audit by the Japanese Pharmaceutical and Medical Device Agency (PMDA) for the review of a sterile injectable client product. Draxis Pharma, based in Montreal, Quebec, Canada, also completed a successful audit by the US Food and Drug Administration (FDA) and Health Canada.

HollisterStier

The audit by the Japanese Pharmaceutical and Medical Device Agency (PMDA) revealed no significant observations, which has resulted in a recommendation to the MHLW that Hollister-Stier be listed as an approved manufacturing site for the client's product. Independent of the PMDA audit, the HollisterStier facility was also recently approved by the European Medicines Agency (EMA) as a manufacturing site for this same product.

Draxis Pharma

The audit of Draxis Pharma by the US Food and Drug Administration (FDA) included a comprehensive cGMP review of both sterile parenteral and non-sterile semi-solid manufacturing capabilities and a Pre-Approval Inspection for three client products. No observations were received from this audit. Recommendations for site approvals for the three new client products are expected. The audit of Draxis Pharma by Health Canada focused on a cGMP review of a dedicated packaging capability and revealed no significant audit observations.

Marcelo Morales, CEO of HollisterStier Contract Manufacturing and Draxis Pharma, said "We are extremely pleased with the audit findings at both our HollisterStier and Draxis Pharma facilities. Maintaining a rigorous quality culture and robust quality systems, combined with effectively managing our clients' projects, assures the success of these projects in the global market place."

About Jubilant Organosys

Jubilant Organosys Limited., an integrated pharmaceutical industry player, is the largest custom research and manufacturing services (CRAMS) out of India. The company has a presence across the pharmaceutical value chain for providing products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables & non-sterile products, radiopharmaceuticals, generic dosage forms, drug discovery services, medicinal chemistry services, clinical research services, Life Science Chemicals, Nutrition Ingredients and Health Care. The Company also manufactures Agri and Performance Polymer products. For more information please visit : www.jubl.com

About HollisterStier Contract Manufacturing and DRAXIS Pharma

HollisterStier Contract Manufacturing and DRAXIS Pharma are separately branded contract manufacturing organizations that joined capabilities and services under the ownership of Jubilant Organosys. HollisterStier is a global manufacturing service provider, able to aseptically fill liquid and lyophilized products at their Spokane, Washington, U.S.A., facility and DRAXIS Pharma offers manufacturing services for sterile liquid and sterile and non-sterile semi-solid dosage forms at their Montreal, Quebec, Canada, facility. Manufacturing facilities for solid dosage forms are also available in the United States and India through HollisterStier and DRAXIS.

 Both organizations offer highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. HollisterStier and DRAXIS are committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities. For more information about HollisterStier Contract Manufacturing, please visit HScontract.com and for more information about DRAXIS Pharma, visit www.DRAXISPharma.com.

HollisterStier-Draxis Pharma
Media Inquiries:
Shannon Jordan
509.482.4958

Spokane, Washington, U.S.A. March 15, 2010 - Jubilant Organosys, a leading integrated pharma and life sciences company headquartered in India, announced today that two of its contract manufacturing facilities in North America successfully completed regulatory authority cGMP audits, recently. HollisterStier Contract Manufacturing, based in Spokane Washington, U.S.A, completed a successful audit by the Japanese Pharmaceutical and Medical Device Agency (PMDA) for the review of a sterile injectable client product. Draxis Pharma, based in Montreal, Quebec, Canada, also completed a successful audit by the US Food and Drug Administration (FDA) and Health Canada.

HollisterStier

The audit by the Japanese Pharmaceutical and Medical Device Agency (PMDA) revealed no significant observations, which has resulted in a recommendation to the MHLW that Hollister-Stier be listed as an approved manufacturing site for the client's product. Independent of the PMDA audit, the HollisterStier facility was also recently approved by the European Medicines Agency (EMA) as a manufacturing site for this same product.

Draxis Pharma

The audit of Draxis Pharma by the US Food and Drug Administration (FDA) included a comprehensive cGMP review of both sterile parenteral and non-sterile semi-solid manufacturing capabilities and a Pre-Approval Inspection for three client products. No observations were received from this audit. Recommendations for site approvals for the three new client products are expected. The audit of Draxis Pharma by Health Canada focused on a cGMP review of a dedicated packaging capability and revealed no significant audit observations.

Marcelo Morales, CEO of HollisterStier Contract Manufacturing and Draxis Pharma, said "We are extremely pleased with the audit findings at both our HollisterStier and Draxis Pharma facilities. Maintaining a rigorous quality culture and robust quality systems, combined with effectively managing our clients' projects, assures the success of these projects in the global market place."

About Jubilant Organosys

Jubilant Organosys Ltd., an integrated pharmaceutical industry player, is the largest custom research and manufacturing services (CRAMS) out of India. The company has a presence across the pharmaceutical value chain for providing products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables & non-sterile products, radiopharmaceuticals, generic dosage forms, drug discovery services, medicinal chemistry services, clinical research services, Life Science Chemicals, Nutrition Ingredients and Health Care. The Company also manufactures Agri and Performance Polymer products. For more information please visit : www.jubl.com

About HollisterStier Contract Manufacturing and DRAXIS Pharma

HollisterStier Contract Manufacturing and DRAXIS Pharma are separately branded contract manufacturing organizations that joined capabilities and services under the ownership of Jubilant Organosys. HollisterStier is a global manufacturing service provider, able to aseptically fill liquid and lyophilized products at their Spokane, Washington, U.S.A., facility and DRAXIS Pharma offers manufacturing services for sterile liquid and sterile and non-sterile semi-solid dosage forms at their Montreal, Quebec, Canada, facility. Manufacturing facilities for solid dosage forms are also available in the United States and India through HollisterStier and DRAXIS.

 Both organizations offer highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. HollisterStier and DRAXIS are committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities. For more information about HollisterStier Contract Manufacturing, please visit HScontract.com and for more information about DRAXIS Pharma, visit www.DRAXISPharma.com.

HollisterStier-Draxis Pharma
Media Inquiries:
Shannon Jordan
509.482.4958

Spokane, Washington, U.S.A. March 15, 2010 - Jubilant Organosys, a leading integrated pharma and life sciences company headquartered in India, announced today that two of its contract manufacturing facilities in North America successfully completed regulatory authority cGMP audits, recently. HollisterStier Contract Manufacturing, based in Spokane Washington, U.S.A, completed a successful audit by the Japanese Pharmaceutical and Medical Device Agency (PMDA) for the review of a sterile injectable client product. Draxis Pharma, based in Montreal, Quebec, Canada, also completed a successful audit by the US Food and Drug Administration (FDA) and Health Canada.

HollisterStier

The audit by the Japanese Pharmaceutical and Medical Device Agency (PMDA) revealed no significant observations, which has resulted in a recommendation to the MHLW that Hollister-Stier be listed as an approved manufacturing site for the client's product. Independent of the PMDA audit, the HollisterStier facility was also recently approved by the European Medicines Agency (EMA) as a manufacturing site for this same product.

Draxis Pharma

The audit of Draxis Pharma by the US Food and Drug Administration (FDA) included a comprehensive cGMP review of both sterile parenteral and non-sterile semi-solid manufacturing capabilities and a Pre-Approval Inspection for three client products. No observations were received from this audit. Recommendations for site approvals for the three new client products are expected. The audit of Draxis Pharma by Health Canada focused on a cGMP review of a dedicated packaging capability and revealed no significant audit observations.

Marcelo Morales, CEO of HollisterStier Contract Manufacturing and Draxis Pharma, said "We are extremely pleased with the audit findings at both our HollisterStier and Draxis Pharma facilities. Maintaining a rigorous quality culture and robust quality systems, combined with effectively managing our clients' projects, assures the success of these projects in the global market place."

About Jubilant Organosys

Jubilant Organosys Limited., an integrated pharmaceutical industry player, is the largest custom research and manufacturing services (CRAMS) out of India. The company has a presence across the pharmaceutical value chain for providing products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables & non-sterile products, radiopharmaceuticals, generic dosage forms, drug discovery services, medicinal chemistry services, clinical research services, Life Science Chemicals, Nutrition Ingredients and Health Care. The Company also manufactures Agri and Performance Polymer products. For more information please visit : www.jubl.com

About HollisterStier Contract Manufacturing and DRAXIS Pharma

HollisterStier Contract Manufacturing and DRAXIS Pharma are separately branded contract manufacturing organizations that joined capabilities and services under the ownership of Jubilant Organosys. HollisterStier is a global manufacturing service provider, able to aseptically fill liquid and lyophilized products at their Spokane, Washington, U.S.A., facility and DRAXIS Pharma offers manufacturing services for sterile liquid and sterile and non-sterile semi-solid dosage forms at their Montreal, Quebec, Canada, facility. Manufacturing facilities for solid dosage forms are also available in the United States and India through HollisterStier and DRAXIS.

 Both organizations offer highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. HollisterStier and DRAXIS are committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities. For more information about HollisterStier Contract Manufacturing, please visit HScontract.com and for more information about DRAXIS Pharma, visit www.DRAXISPharma.com.

HollisterStier-Draxis Pharma
Media Inquiries:
Shannon Jordan
509.482.4958

SPOKANE, Washington, USA, October 9, 2009- HollisterStier Contract Manufacturing and sister organization, DRAXIS Pharma, announced today the appointment of Steven Rowan as lead of the companies' North American contract manufacturing business development division.

HollisterStier Contract Manufacturing and DRAXIS Pharma are separately branded contract manufacturing organizations that joined capabilities and services under the ownership of Jubilant Organosys. Mr. Rowan joins the Jubilant Organosys organization as Vice President of Business Development, Jubilant Organosys Contract Manufacturing North America, and will oversee a HollisterStier-DRAXIS corporate business development team. Mr. Rowan will be responsible for global business development activities for HollisterStier Contract Manufacturing and DRAXIS Pharma as well as establishing strategic partnerships to strengthen the companies' presence throughout Europe and Asia.

Mr. Rowan is an industry veteran with over twenty years of experience in the pharmaceutical and bio-pharmaceutical industries. His in-depth knowledge, extensive scientific background and experience implementing Six Sigma methodologies will benefit the organizations as they more closely align their manufacturing services.

"I look forward to being a part of this team as we transition into having a more heightened global presence," said Mr. Rowan. "Together, we offer a level of technical expertise, multiple dosage forms, and understanding of the entire life cycle that proves to be very competitive in the outsourcing industry - this is an exciting opportunity for me to help showcase our competitive advantages and strategically position HollisterStier and DRAXIS Pharma as leading industry players."

About Jubilant Organosys

Jubilant Organosys Ltd., an integrated pharmaceutical industry player, is the largest custom research and manufacturing services (CRAMS) out of India. The company has a presence across the pharmaceutical value chain for providing products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables & non-sterile products, radiopharmaceuticals, generic dosage forms, drug discovery services, medicinal chemistry services, clinical research services, and Health Care. The Company also manufactures Industrial and Performance products. For more information please visit : www.jubl.com

About HollisterStier Contract Manufacturing and DRAXIS Pharma

HollisterStier Contract Manufacturing and DRAXIS Pharma are separately branded contract manufacturing organizations that joined capabilities and services under the ownership of Jubilant Organosys. HollisterStier is a global manufacturing service provider, able to aseptically fill liquid and lyophilized products at their Spokane, Washington, U.S.A., facility and DRAXIS Pharma offers manufacturing services for sterile liquid and sterile and non-sterile semi-solid dosage forms at their Montreal, Quebec, Canada, facility. Manufacturing facilities for solid dosage forms are also available in the United States and India through HollisterStier and DRAXIS.

Both organizations offer highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. HollisterStier and DRAXIS are committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities. For more information about HollisterStier Contract Manufacturing, please visit HScontract.com and for more information about DRAXIS Pharma, visit www.DRAXISPharma.com.